ICQA Musing

2018-07-09T22:42:55+00:00

The 9th International CoQ10 Conference has concluded. I have to begin by saying I have never been prouder of this category than I am right now. The Conference was expertly presented by an amazing staff and sponsored by dedicated companies. Primary supporters were Kaneka, Pharma Nord, MSE Pharmazeutika, Jarrow Formulas and Cienporcien Natural. The attendees consisted of over 100 researchers, clinicians and other focused healthcare professionals, all demonstrating an unparalleled commitment for CoQ10 and the promise it provides. The passion of the researchers supporting CoQ10 was unlike anything I have seen with most other ingredients but was consistent with previous ICQA Conferences.

There were 46 lecture presentations and 40 Poster presentations. Selenium was a surprisingly popular co-topic of intense interest with one titled lecture, one titled poster and many other references. An impressive discussion was presented by Dr. Urban Alehagen, Division of Cardiovascular Medicine, Linkoping University on a high-selenium yeast / CoQ10 combination study. The study conclusion indicated a 54% reduction of mortality by cardiovascular disease. Dr. Alehagen discussed the KiSel-10 Study conducted between 2003 and 2010 where 443 elderly members of a small Swedish village, Kisa, Sweden. Men and women aged 70-87 were provided a combination of 200mg of CoQ10 and 200mcg of selenium yeast or matching placebo for 4 years. The study and analysis has generated a dozen published papers.

Additionally, discussions supporting the science of CoQ10 was demonstrated in areas such as:

  • Mitochondrial dysfunction
  • Statin treatment including associated cognitive decline
  • Healthy aging
  • Reproductive aging
  • Chronic diseases
  • Diabetes
  • Critical Illness
  • Chronic pain
  • Fatigue, sleep and oxidative stress
  • Fragile X Syndrome
  • Glaucoma
  • Skin Care / Wrinkle Reduction

Dr. Nancy Klimas, Immunologist, Nova Southeastern University Miami, South Florida Veteran’s Affairs Foundation, gave an important update on the use of Ubiqinol in treating Gulf War Illness. This study has already concluded Phase I and II trials and proceeding into phase III trials. The impact of the serin gas exposure the Veterans were exposed to is still being discovered today.

CoQ10 usage has been advancing in combination with the science and consumer results supporting the benefits the ingredient offers. While the body of evidence to support CoQ10 is strong, the attendees at the Conference were all in agreement that more research can and should be done.

~Scott